Skip to main content

August 2022

academics

 

Clinical research courses

Job for KAM Head in Government Business at Zydus Lifesciences Ltd

After a journey of growth spanning 27 years as Cadila Healthcare Ltd. and the Zydus Group, we have evolved and transformed ourselves in response to the changing times. Our legacy of over 70 years in healthcare and being dedicated to life in all its dimensions is reaffirmed in our new mission, vision and purpose. Unifying ourselves under the Zydus name, Cadila Healthcare Ltd., is renamed as Zydus Lifesciences Ltd.

Post : KAM Head - Government Business

Novo Nordisk looking for Manager Medical Affairs

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within Haemophilia care, growth hormone therapy and hormone replacement therapy.

Post : Manager Medical Affairs (RWE team)

Admission to Central University of Rajasthan Admission 2022-23

The Central University of Rajasthan has been established by an Act of Parliament (Act No. 25 of 2009) as a new Central University, and is fully funded by the Government of India. The President of India, Her Excellency Smt. Droupadi Murmu, is the Visitor of the CURAJ. Prof. Anand Bhalerao is the Vice Chancellor of the University. CURAJ is located in Ajmer district of Rajasthan.

Walk in interview for M.Pharm, B.Pharm in Packing, Production, Technical Services Department at Macleods

Macleods Pharmaceuticals, India's fastest growing company was established in 1986. Ranked amongst the top 10 pharma companies with a strength of 20000 employees, operating in 140 plus countries. Our bioequivalence centre was established in 2005 and is responsible for conducting studies for filing product registrations with various regulatory authorities.

Walk in interview for M.Pharm, B.Pharm in Production Department at Sri Krishna Pharmaceuticals Ltd

Sri Krishna Pharmaceuticals Ltd, established in 1974, started life as a pioneer in the bulk manufacture of acetaminophen (Paracetamol) for the domestic Indian market. Today, the company is a vertically integrated bulk manufacturer of multiple first-line-of-defence APIs, PFIs and finished dosage drugs. Paracetamol is still very important to the company and the company remains one of the largest manufacturers in the world.

Vacancy for M.Pharm, B.Pharm in Production, Packing Department at Macleods Pharmaceuticals

Macleods Pharmaceuticals, India's fastest growing company was established in 1986. Ranked amongst the top 10 pharma companies with a strength of 20000 employees, operating in 140 plus countries. Our bioequivalence centre was established in 2005 and is responsible for conducting studies for filing product registrations with various regulatory authorities.

Vacancy for M.Pharm, B.Pharm, M.Sc in API Unit at Optimus Research

Optimus was established in the year 2004 as custom synthesis laboratory by a team of Technocrats. It is one of the fastest growing Manufacturer in Active Pharmaceutical Ingredients (APIs) and Finished dosages. We expanded into global markets and started filing DMFs for both APIs and Intermediates with various Regulatory agencies. Optimus Research Center for API & Formulations was set-up as a centralized Research and Development center to focus on Generic product developments suitable for regulated markets.

Syneos Health require Senior Medical Writer

Syneos Health is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, seamlessly connecting our capabilities to add high-value insights to speed therapies to patients and provide practical value to help our customers achieve their objectives.

Post : Senior Medical Writer

Polypill reduces cardiovascular mortality by 33% in patients treated after a heart attack

A three-drug medication known as a polypill, developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer, is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this patient population.  These are findings from the SECURE trial led by Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, and General Director of CNIC.

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

Bayer announced the start of a Phase III clinical development program OCEANIC to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor, as a potential new treatment in patients with atrial fibrillation and in patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack.